Cardiol Therapeutics Inc - Ordinary Shares - Class A

+0.02 (+2.27%)
: $0.92 +0.02 (+2.22%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:CRDL

2265 Upper Middle Road East, Suite 602, Oakville, Ontario L6H 0G5
Phone: +1.289.910.0850
Number of Employees: 22


Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.